AstraZeneca's Imfinzi gets NICE nod for lung cancer

March 28, 2019

The National Institute for Health and Care Excellence (NICE) said it would cover AstraZeneca's Imfinzi via the Cancer Drugs Fund, for the treatment of certain patients with non-small-cell lung cancer.

Specifically, the drug is for patients suffering from locally advanced unresectable non-small cell lung cancer (stage 3) who have already had another type of treatment (platinum-based chemoradiation).

Imfinzi was approved last September on the basis of data from a Phase III trial that showed the drug induced a statistically significant improvement in progression-free survival by 11.2 months versus placebo. According to NICE, there are currently no other treatment options for these patients whose disease has not progressed post-chemoradiation.

Offered to the NHS at a discounted price, the drug could benefit around 165 people in England in its first year, with more to follow, according to Nice.

Read the NICE release.